New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT05838768
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called HRO761, alone or combined with pembrolizumab or irinotecan, in people with advanced solid tumors that have high microsatellite instability (MSI-high) or mismatch repair deficiency (dMMR). The main goals are to check safety and find the best dose. About 123 participants whose cancers have not responded to prior treatments will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRO761 (tablet), pembrolizumab (infusion), irinotecan (infusion)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced cancers that have specific genetic markers (MSI-high or dMMR).
What could go wrong
This is an early Phase 1 trial with only 123 participants, focused on safety and dosing. It is too soon to know if HRO761 will work, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Ctr
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering
New York, New York, 10017, United States
-
Novartis Investigative Site
Brussels, 1200, Belgium
-
Novartis Investigative Site
Beijing, 100036, China
-
Novartis Investigative Site
Guangzhou, 510655, China
-
Novartis Investigative Site
Bordeaux, 33076, France
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Kashiwa, Chiba, 2778577, Japan
-
Novartis Investigative Site
Oslo, 0310, Norway
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Seoul, 03722, South Korea
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28040, Spain
-
Novartis Investigative Site
Valencia, 46010, Spain
-
Novartis Investigative Site
Stockholm, 17176, Sweden
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
London, SW3 6JJ, United Kingdom
-
Novartis Investigative Site
Oxford, OX3 7LE, United Kingdom
-
UCSF
San Francisco, California, 94115, United States
-
Univ of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
University of California LA
Los Angeles, California, 90095, United States